Skip to main content
    L

    Liminatus Pharma, Inc. Class A Common Stock (LIMN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.97
    -0.02 (-0.67%)

    Market Cap: $4.02M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    Liminatus Pharma, Inc. Class A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$10.21M, operating cash flow was -$9.96M and free cash flow was -$9.98M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$1.41M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $2.97M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Research and development$0$2.69M$3.76M$1.85M$3.80M
    Operating income-$2.97M-$3.33M-$2.59M-$2.71M-$2.53M
    Net income-$10.21M-$3.55M-$1.23M-$2.93M$4.37M
    EBITDAN/A-$3.33M-$1.09M-$2.71M$4.37M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Gross profit$0$0$255$0$0$0N/A$0$0$0N/AN/A
    Operating income-$1.38M-$1.10M-$1.15M-$701.17K-$1.12M-$264.22K-$1.88M-$543.15K-$909.22K-$247-$642.70K-$676.32K
    Net income-$1.41M-$1.12M-$8.50M-$1.82M$113.29K-$327.53K-$1.98M-$601.37K-$961.21K-$247-$486.60K-$323.89K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $1.44M exceeded cash and equivalents by $1.10M. Shareholder equity was negative, at -$9.81M, as total liabilities of $10.33M exceeded total assets of $512.79K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$512.79K$5.41M$4.50M$15.49M$276.44M
    Current assets$500.57K$5.28M$210.88K$360.65K$421.92K
    Cash and equivalents$337.65K$56.32K$434.00K$5.05M$336.23K
    Total liabilities$10.33M$24.75M$15.19M$14.19M$21.57M
    Short-term debt$1.44M$19.97M$16.05M$16.50M$90.00K
    Shareholder equity-$9.81M-$19.34M-$10.69M$1.29M$254.87M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$3.40M$2.79M$512.79K$1.34M$1.91M$0$5.41M$3.07M$3.54M$4.63M$4.50M$4.56M
    Total liabilities$3.10M$2.92M$10.33M$2.99M$10.72M$1.06K$24.75M$17.32M$16.61M$17.16M$15.19M$14.76M
    Cash and equivalents$3.02M$1.91M$337.65K$724.50K$1.34M$804.54K$56.32K$358.18K$339.20K$1.47M$434.00K$337.72K
    Shareholder equity$300.61K-$132.60K-$9.81M-$1.65M-$8.81M-$1.06K-$19.34M-$14.25M-$13.07M-$12.53M-$10.69M-$10.21M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$9.96M-$1.45M-$3.35M-$869.00K-$1.22M
    Capital expenditures$13.11K$0$0$0$0
    Free cash flow-$9.98M-$1.45M-$3.35M-$869.00K-$1.22M
    Dividends paid$2.56M$0N/AN/AN/A
    Investing cash flow-$788.11K-$2.85M-$819.00K$263.96M-$276.00M
    Financing cash flow$11.03M$3.92M-$450.00K$5.92M$277.55M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$970.00K-$2.02M-$386.85K-$600.61K-$8.82M-$159.39K-$140.66K-$206.12K-$1.10M$0-$627.10K-$539.35K
    Capital expendituresN/A$0$0$13.11K$0$0$5$5$3$0$1$3
    Free cash flowN/A-$2.02M-$386.85K-$613.72K-$8.82M-$159.39K-$140.66K-$206.12K-$1.10M$0-$627.10K-$539.36K
    Last 12 quarters

    Frequently Asked Questions About LIMN

    What is Liminatus Pharma, Inc. Class A Common Stock's annual revenue?

    Liminatus Pharma, Inc. Class A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Liminatus Pharma, Inc. Class A Common Stock profitable?

    No. Liminatus Pharma, Inc. Class A Common Stock reported net income of -$10.21M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does LIMN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.96M minus capital expenditures of $13.11K produced free cash flow of -$9.98M.

    How much debt does Liminatus Pharma, Inc. Class A Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.44M and cash and equivalents of $337.65K.